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ABSTRACT
Background: Recent studies have suggested that mel-
atonin—a hormone produced by the pineal gland
under circadian control—contributes to PD-related
sleep dysfunction. We hypothesized that degenerative
changes to the neural structures controlling pineal
function (especially the suprachiasmatic nuclei of the
anterior hypothalamus) may be responsible for reduced
melatonin output in these patients. We compared
hypothalamic volumes in PD patients with matched
controls and determined whether volume loss corre-
lated with reduced melatonin output in the PD group.
Methods: A total of 12 PD patients and 12 matched
controls underwent magnetic resonance imaging to
determine hypothalamic volume. In addition, PD
patients underwent 24-hour blood sampling in a con-
trolled environment to determine serum melatonin con-
centrations using enzyme-linked immunosorbent
assays.
Results: PD patients had significantly reduced hypo-
thalamic gray matter volume when compared with
matched controls. Melatonin levels were significantly
associated with hypothalamic gray matter volume and
disease severity in PD patients.
Conclusion: Melatonin levels are associated with hypo-
thalamic gray matter volume loss and disease severity
in PD patients. This provides anatomical and physiolog-
ical support for an intrinsic sleep and circadian pheno-
type in PD. VC 2016 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Inter-
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Sleep disturbances are one of the most common
nonmotor complaints in Parkinson’s disease (PD) and
have been attributed to a variety of factors. Under-
standing the relative contribution of each is crucial to
identify the most effective treatment strategies for indi-
vidual patients. Some of these relate to the clinically
identified features of the disease such as motor impair-
ment, nocturia, pain, or neuropsychiatric symptoms.
Dopaminergic and other medications may also exacer-
bate patients’ sleep problems. However, the sleep dys-
function in PD may be a result of neuronal loss in key
structures and circuits involved in the regulation of
the sleep-wake cycle.
Two recent studies have reported that reduced mela-
tonin output in PD patients is associated with altered
sleep architecture, including reduced slow wave and
rapid eye movement sleep1 and excessive daytime
sleepiness.2 Altered melatonin patterns have also been
observed in Huntington’s disease3 and Alzheimer’s dis-
ease,4 both of which have prominent sleep and circa-
dian abnormalities. Because melatonin is a hormone
produced by the pineal gland under circadian control,
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we hypothesised that degenerative changes to the neu-
ral structures controlling pineal function (especially
the suprachiasmatic nuclei [SCN] of the hypothala-
mus) may reduce melatonin output and contribute to
certain aspects of sleep dysfunction in PD.
This study compared hypothalamic volumes in PD
patients with matched controls and determined
whether volume loss correlated with reduced melato-
nin output in the PD group.
Methods
Patients
A total of 12 PD patients were selected from a pre-
viously studied sleep cohort.1 All of the patients who
had also undergone magnetic resonance imaging
(MRI) as part of the parallel Incidence of Cognitive
Impairment in Cohorts with Longitudinal Evaluation–
Parkinson’s Disease (ICICLE-PD) study were included
in the analysis, in addition to 12 unrelated matched
controls from the Medical Research Council
Cognition and Brain Sciences Unit healthy volunteer
panel. The ICICLE-PD protocol has been published
elsewhere.5 All participants provided written consent,
the study was performed according to the Declaration
of Helsinki, and the protocol was approved by the
local research ethics committee.
In brief, patients underwent a battery of clinical
tests including the Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS), Addenbrooke’s Cognitive Exam-
ination (ACE-R), and the Beck Depression Inventory
(BDI). Levodopa equivalent dose (LED) was calculated
using the conversion factors proposed by Tomlinson
and colleagues.6 Matching was based on age, gender,
years of education, and ACE-R.
Imaging Acquisition and Analysis
MRI data were acquired using a Siemens TIM Trio
3T scanner (Siemens Medical Systems, Erlangen, Ger-
many). Patients underwent T1-weighted magnetisation
prepared rapid gradient echo scanning: pulse repeti-
tion5 2250 ms, echo time52.98 ms, flip angle59 8,
time delay5 900 ms, 2563 256 mm2 field of view,
1923 1 mm slices). Images were preprocessed accord-
ing to a pipeline in SPM8 (http://www.fil.ion.ucl.ac.
uk/spm) run on Matlab 7 (Mathworks, Natick, Mas-
sachusetts). T1-weighted images were segmented into
gray matter and white matter tissue and registered
through the Diffeomorphic Anatomical Registration
Through Exponentiated Lie Algebra scheme. The
resulting study-specific template was registered to
Montreal Neurological Institute space, and individual
modulated images were smoothed with an 8 mm, full
width at half-maximum Gaussian kernel. A hypothala-
mic region of interest (dilated by 3 mm) from the
WFU Pick Atlas (http://fmri.wfubmc.edu/software/
pickatlas) was used to obtain an individual hypothala-
mic volume per participant (Fig. 1A,B). Gray matter
volume in the region of interest (measured in voxels)
was calculated using the FMRIB Software Library
(FSL) tool “fslstats” within FSL version 4.1.7 (www.
fmrib.ox.ac.uk). Thereafter, relative hypothalamic
gray matter volume was calculated by dividing by
whole brain volume (the sum of the gray and white
matter segments).
Serum Melatonin Measurement
PD patients were admitted to a single room at the
Wellcome Trust Clinical Research Facility at Adden-
brooke’s Hospital in Cambridge. A peripheral venous
cannula was inserted 30 minutes before the start of
sampling at 1:00 PM. During the next 24 hours, partic-
ipants adhered to their habitual bed times, and blood
samples were collected every 90 minutes using a 3-
way valve that was attached to a 0.9% sodium chlo-
ride infusion to prevent the cannula from clotting.
Sampling was performed through a long line to pre-
vent disruption to the patient’s sleep. Participants
remained sedentary apart from bathroom visits. Meal
times were consistent between participants, and no
daytime naps were allowed. Temperature was constant
at 21 8C. Patients were not strictly shielded from exter-
nal light, but lighting levels were less than 5 lux fol-
lowing lights off. Serum melatonin concentrations
were measured using enzyme-linked immunosorbent
assays as previously described.1 Based on hormone
concentrations at each 90-minute time point, total 24-
hour melatonin output was defined as the area under
the curve (calculated using the trapezoid rule).
Statistical Analysis
All data were approximately normally distributed
based on Shapiro-Wilk testing; therefore, unpaired t
tests were used to compare clinical parameters and
volumetric values between patients and controls. Pear-
son rank correlation testing was used to study the
relationship between melatonin output and relative
hypothalamic gray matter volume, as well as the rela-
tionship between melatonin output and disease sever-
ity (adjusted for LED).
Results
Age, gender, duration of education, and ACE-R
were not significantly different between PD patients
and controls (Table 1). PD patients had a mean dis-
ease duration of 3.3 years, mean LED of 366 mg, and
mean UPDRS part III score of 23.9. None of the par-
ticipants were taking hypnotics. The mean duration
between melatonin testing and MRI in the PD group
was 1.9 months (SD 3.4).
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When compared with controls, PD patients had sig-
nificantly reduced relative hypothalamic gray matter
volume (2.563 1027 [SD 2.7831027] vs 2.6931027
[SD 2.073 1027]; P5 .005) (Fig. 1C).
Having verified that there were significant differen-
ces between patients and controls in terms of hypo-
thalamic volume, we found that melatonin levels were
significantly associated with relative hypothalamic
gray matter volume in the PD group (r5 .591,
P5 .028) (Fig. 1D).
Partial correlation between melatonin levels and dis-
ease severity, correcting for LED, showed a significant
inverse relationship (r52.681, P5 .021). There was
no significant relationship between melatonin output
and LED (r5 .180, P5 .76).
Discussion
There is increasing evidence from clinical and ani-
mal studies that there is circadian dysregulation in a
variety of neurodegenerative diseases.7 We previously
reported significant reductions in melatonin concentra-
tion in 30 early-stage PD patients.1 Videnovic and col-
leagues also found a significantly diminished
amplitude of melatonin secretion in serum samples of
20 PD patients on dopaminergic therapy under modi-
fied constant routine conditions.2
There is evidence from neuropathological8 and
imaging9 studies that the hypothalamus is directly
affected by PD. The central clock within the hypothal-
amus, the SCN, is likely to contribute to this volume
loss because it has been shown that mice overexpress-
ing alpha-synuclein exhibit a reduced SCN firing
rate.10 This could weaken their ability to communicate
neural and hormonal signals from the central clock to
the pineal gland, which secretes melatonin into the
blood.
TABLE 1. Clinical characteristics of PD
patients and controls
Variable PD Controls P valued
Number of participants 12 12 na
Gender ratio (male:female) 6:6 6:6 1.0
Age (years) 66.7 (5.5) 66.3 (5.2) 0.92
Duration of education (years) 18.3 (2.9) 17.2 (2.8) 0.33
ACE-R 95.2 (3.1) 96.1 (3.0) 0.48
Disease duration (years)a 3.3 (1.1) na na
LEDD (mg)b 366 (161) na na
MDS-UPDRS part IIIc 23.9 (9.0) na na
BDI 7.3 (17.8) 3.3 (3.6) 0.011*
*Significant difference at .05 level.
LEDD, levodopa equivalent daily dose; ACE-R, Addenbrooke’s Cognitive
Examination-Revised; MDS-UPDRS, Unified Parkinson’s Disease Rating
Scale; BDI, Beck Depression Inventory; na, not applicable.
Results expressed as mean (SD) unless stated otherwise
*Significant difference at .05 level.
aDisease duration from date of diagnosis.
bAll but two PD patients were taking dopaminergic medication.
cBased on MDS-UPDRS assessments performed within the last 6 months.
dUnpaired t tests performed.
FIG. 1. A and B: Panels show the region of interest used to calculate the hypothalamic volume for each participant. C: Panel is a graphical representa-
tion of the significant reduction in relative hypothalamic gray matter volume in PD patients when compared with matched controls (with standard error
of the mean error bars). D: Panel demonstrates the significant correlation between relative hypothalamic gray matter volume and total 24-hour melato-
nin output (with both axes showing partial residuals). In both graphs, relative hypothalamic gray matter volume was calculated by dividing gray matter
volume by whole brain volume (both measured in voxels). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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This study thus adds to the existing literature by
suggesting that hypothalamic volume loss—which we
have now shown in this new PD cohort—may be
responsible for reduced melatonin output, which has
been linked to sleep disturbances in PD.
The major limitation of this study is the relatively
small number of patients, which precluded the use of
linear regression and adjustment of confounders. Fur-
thermore, patients were not strictly shielded from exter-
nal light during the melatonin sampling period, which
may have influenced the results. Although we lacked
serum melatonin measurements in the control group,
the critical test for our hypothesis was the correlation
between hypothalamic volume and melatonin levels in
PD patients. It is not yet possible to perform dedicated
imaging of the SCN within the hypothalamus using
3Tesla MRI; therefore, ultra-high field imaging or
clinico-pathological studies will be required to allow
more thorough dissection of the relative role of the dif-
ferent hypothalamic nuclei to this deficit.
In summary, we have shown that melatonin levels are
associated with hypothalamic gray matter volume loss
and disease severity in PD patients. This provides anatom-
ical and physiological support for an intrinsic sleep and
circadian phenotype in PD and the fact that this is related
to the disease itself rather than being an indirect conse-
quence of other symptoms or treatments.
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